\n\u00a0<\/p>\n
UNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\n\u00a0<\/p>\n
Form 6-K<\/p>\n
\n\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
\n15d-16<\/p>\n
UNDER THE SECURITIES EXCHANGE ACT OF 1934<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nFor the
\nmonth of August 2026<\/p>\n
\n\u00a0<\/p>\n
\nCommission
\nFile Number 001-15170<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
GSK plc<\/p>\n
\n(Translation
\nof registrant’s name into English)<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
79 New Oxford Street, London, WC1A 1DG<\/p>\n
\n(Address
\nof principal executive office)<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F.<\/p>\n
\n\u00a0<\/p>\n
\nForm
\n20-F . . . .X. . . . Form 40-F . . . . . . . .<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
GSK plc\u00a0(the
\n‘Company’)<\/p>\n
Transaction notification<\/p>\n
1.<\/p>\n
Details of PDMR\/person closely associated with them
\n(‘PCA’)<\/p>\n
\n\u00a0<\/p>\n
\na)<\/p>\n
\n\u00a0<\/p>\n
\nName<\/p>\n
Maya Martinez-Davis<\/p>\n
\n\u00a0<\/p>\n
\nb)<\/p>\n
\nPosition\/status<\/p>\n
President, US<\/p>\n
\n\u00a0<\/p>\n
\nc)<\/p>\n
\nInitial
\nnotification\/ amendment<\/p>\n
Initial notification<\/p>\n
\n\u00a0<\/p>\n
2.<\/p>\n
Details of the issuer, emission allowance market participant,
\nauction platform, auctioneer or auction monitor<\/p>\n
\n\u00a0<\/p>\n
\na)<\/p>\n
\nName<\/p>\n
GSK plc<\/p>\n
\n\u00a0<\/p>\n
\nb)<\/p>\n
\nLEI<\/p>\n
5493000HZTVUYLO1D793<\/p>\n
\n\u00a0<\/p>\n
3.<\/p>\n
Details of the transaction(s): section to be repeated for (i) each
\ntype of instrument; (ii) each type of transaction; (iii) each date;
\nand (iv) each place where transaction(s) has been
\nconducted<\/p>\n
\n\u00a0<\/p>\n
\na)<\/p>\n
\nDescription
\nof the financial instrument<\/p>\n
American Depositary Shares (‘ADS’)<\/p>\n
\u00a0<\/p>\n
ISIN:\u00a0US37733W2044<\/p>\n
\n\u00a0<\/p>\n
\nb)<\/p>\n
\nNature
\nof the transaction<\/p>\n
Acquisition of notional ADS within Ms Martinez-Davis’s GSK
\nExecutive Supplemental Savings Plan account<\/p>\n
\u00a0<\/p>\n
\nc)<\/p>\n
\nPrice(s)
\nand volume(s)<\/p>\n
Price(s)<\/p>\n
\n\u00a0<\/p>\n
\nVolume(s)<\/p>\n
$52.9600<\/p>\n
\n\u00a0<\/p>\n
9.016<\/p>\n
\nd)<\/p>\n
\nAggregated
\ninformation<\/p>\n
\n\u00a0<\/p>\n
N\/A (single transaction)<\/p>\n
\nAggregated
\nvolume Price<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\ne)<\/p>\n
\nDate
\nof the transaction<\/p>\n
2026-08-07<\/p>\n
\n\u00a0<\/p>\n
\nf)<\/p>\n
\nPlace
\nof the transaction<\/p>\n
\n\u00a0<\/p>\n
New York Stock Exchange (XNYS)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
About GSK<\/p>\n
GSK is a global biopharma company with a purpose to unite science,
\ntechnology, and talent to get ahead of disease together. Find out
\nmore at\u00a0www.gsk.com.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Registered in England & Wales:<\/p>\n
No.
\n3888792<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Registered Office:<\/p>\n
79
\nNew Oxford Street<\/p>\n
London<\/p>\n
WC1A
\n1DG<\/p>\n
\n\u00a0<\/p>\n
SIGNATURES<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nPursuant
\nto the requirements of the Securities Exchange Act of 1934, the
\nregistrant has duly caused this report to be signed on its behalf
\nby the undersigned, thereunto duly authorised.<\/p>\n
\u00a0<\/p>\n
GSK plc<\/p>\n
\u00a0<\/p>\n
\n(Registrant)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nDate:\u00a0August
\n11, 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nBy:\/s\/\u00a0VICTORIA
\nWHYTE<\/p>\n
\n————————–<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nVictoria\u00a0Whyte<\/p>\n
\u00a0<\/p>\n
\nAuthorised
\nSignatory for and on<\/p>\n
\u00a0<\/p>\n
\nbehalf
\nof GSK plc<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 Form 6-K \u00a0 REPORT OF FOREIGN PRIVATE…\n","protected":false},"author":2,"featured_media":67042,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[32217,32216,35794,31732,20785,21214,5727],"class_list":["post-101397","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-ads-acquisition","tag-american-depositary-shares","tag-executive-supplemental-savings-plan","tag-form-6-k","tag-gsk","tag-gsk-plc","tag-insider-transaction"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117077567166848021","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/101397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=101397"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/101397\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/67042"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=101397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=101397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=101397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}